Evidence map›Paper›PMID 36063207›Full record

SynthesisPsychopharmacology2022

A cumulative Bayesian network meta-analysis on the comparative efficacy of pharmacotherapies for mania over the last 40 years.

Yu Hong, Wenbo Huang, Daiyin Cao, Jilai Xu, Huifan Wei, Jie Zhang, Li Wang

Abstract readSystematic ReviewNetwork Meta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Psychopharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Bipolar disorders: an update on critical aspects.The Lancet regional health. Europe · 2025
    Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 2 countries.

Yu HongPhysical Education Department, Chengdu Sport University, Chengdu, Sichuan, China.
Wenbo HuangClinical Translational Science, Juntendo University Graduate School of Medicine, Bunkyo City, 2 Chome-1-1 Hongo, Tokyo, 113-8421, Japan. 19435061@life.hkbu.edu.hk.ORCID http://orcid.org/0000-0002-6770-9829
Daiyin CaoDepartment of Physical Education, Southwest University, Chongqing, China.
Jilai XuDepartment of Rehabilitation Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Huifan WeiSports Department, Nanchang Institute of Science and Technology, Nanchang, Jiangxi, China.
Jie ZhangMedical & Nursing School, Chengdu University, Chengdu, Sichuan, China.
Li WangDepartment of Physical Education, Hebei Institute of Physical Education, Shijiazhuang, Hebei, China.
Juntendo University · JPChengdu Medical College · CNChengdu Sport University · CNHebei Institute of Physical Education · CNNanchang Institute of Science & Technology · CNSouthwest University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationaleMania (or manic episodes) is a common symptom of bipolar disorder and is frequently accompanied by hyperactivity and delusions; given the cost and resources available, there is a paucity of evidence for direct comparison of different drugs.

objectivesWe aimed to provide evidence-based recommendations on the efficacy of overall currently used pharmacological treatments for patients with acute bipolar mania.

methodWe conducted a systematic review and network meta-analysis (NMA) using a Bayesian network frame. We searched the primary literature databases without language restrictions until Dec 18, 2021, for reports of randomized controlled trials (RCTs) of suspected antimanic drugs used as monotherapy for patients with acute bipolar mania, with the primary outcomes being efficacy (mean difference (MD), standardized mean difference (SMD) in the change of mania score).

resultsEighty-seven studies were included in which 18,724 manic participants (mean age = 34.6 years, with 50.36% males) were allocated at random to one of 25 active medication drug therapies or placebo, resulting in 87 direct comparisons on 192 data points. Tamoxifen (- 22·00 [- 26·00 to - 18·00]) had the best efficacy over the placebo. Meanwhile, risperidone (- 6·60 [- 8·40 to - 4·90]) was substantially more effective than placebo in treating acute mania. Carbamazepine, haloperidol, ziprasidone, cariprazine, olanzapine, quetiapine, aripiprazole, lithium, paliperidone, asenapine, and divalproex were noticeably more effective than placebo.

conclusionsOverall, tamoxifen appears to be the most effective of the currently known pharmaceutical therapy available to treat acute mania or manic episodes; however, this conclusion is restricted by the scale of RCTs conducted, and risperidone was found to be the most effective medication among antipsychotics. Carbamazepine, haloperidol, ziprasidone, cariprazine, olanzapine, quetiapine, aripiprazole, lithium, paliperidone, asenapine, and divalproex were noticeably effective in treating acute mania or manic episodes.

Indexed as

Antimanic AgentsAntipsychotic AgentsAdultAripiprazoleBenzodiazepinesCarbamazepineDibenzocycloheptenesHaloperidolHumansLithiumManiaOlanzapinePaliperidone PalmitatePharmaceutical PreparationsPiperazinesQuetiapine FumarateAntimanic AgentsAntipsychotic AgentsAripiprazoleasenapineBenzodiazepinesCarbamazepineDibenzocycloheptenesHaloperidolLithiumOlanzapinePaliperidone PalmitatePharmaceutical PreparationsPiperazinesQuetiapine FumarateRisperidoneTamoxifenThiazolesValproic AcidziprasidoneEfficacyManiaNetwork meta-analysisPharmacological interventions

Identifiers

PMID36063207
OpenAlexW4294585833

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.